Oxford BioDynamics Plc announced that a study focused on the diagnosis of B-cell lymphoma in dogs has been presented at the American Association for Cancer Research (AACR) Conference on Advances in Liquid Biopsies, which is taking place in Miami, Florida, 13-16 January 2020. OBD presented a paper/poster at the conference entitled: "Development and validation of diagnostic biomarkers for B-cell lymphoma using EpiSwitch™ profiling of whole blood: from humans to canines". The study was conducted in collaboration with the University of Minnesota Department of Veterinary Clinical Sciences, Animal Cancer Care and Research Program, College of Veterinary Medicine and Masonic Cancer Center. OBD utilised its proprietary datasets of markers specific for regulatory 3D genome architecture of lymphoma in humans, as determined using EpiSwitch™, to see if these could be translated from humans into dogs. OBD was able to generate a new biomarker signature using whole blood from a cohort of dogs with lymphoma and validate it on a second cohort. This biomarker signature was able to correctly identify dogs with and without lymphoma with 80% accuracy, 80% sensitivity, 80% specificity, 80% positive predictive value and 80% negative predictive value. The results of this study indicate that EpiSwitch™ biomarkers can be successfully translated across species for related pathologies and conditions. This highlights the potential application of non-invasive EpiSwitch™ biomarkers in new therapeutic developments, including within the veterinary industry.